PTC Therapeutics, Inc. (PTCT)
NASDAQ · Healthcare
PTC Therapeutics, Inc. EBITDA 2011–2025
PTC Therapeutics, Inc. annual/quarterly ebitda history and growth rate from 2015 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- PTC Therapeutics, Inc. ebitda for the quarter ending March 31, 2026 was 60.4 M, a 93.82% decrease year-over-year.
- PTC Therapeutics, Inc. ebitda for the twelve months ending March 31, 2026 was 973.0 M.
- PTC Therapeutics, Inc. annual ebitda for 2025 was 905.8 M, a 499.17% decrease from 2024.
- PTC Therapeutics, Inc. annual ebitda for 2024 was -226.9 M, a 11.83% increase from 2023.
- PTC Therapeutics, Inc. annual ebitda for 2023 was -202.9 M, a 36.31% decrease from 2022.
- PTC Therapeutics, Inc. annual ebitda for 2022 was -318.6 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Ptc Therapeutics Inc. EBITDA — FAQ
Ptc Therapeutics Inc. (PTCT) ebitda over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see PTCT's ebitda history?
The chart and table above show Ptc Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.